$48.64
2.42% yesterday
Nasdaq, Jun 30, 10:17 pm CET
ISIN
CH0334081137
Symbol
CRSP
Sector
Industry

CRISPR Therapeutics AG Stock price

$48.64
+12.35 34.03% 1M
+9.99 25.85% 6M
+9.28 23.58% YTD
-5.31 9.84% 1Y
-12.13 19.96% 3Y
-24.85 33.81% 5Y
+34.55 245.21% 10Y
+34.55 245.21% 20Y
Nasdaq, Closing price Mon, Jun 30 2025
+1.15 2.42%
ISIN
CH0334081137
Symbol
CRSP
Sector
Industry

Key metrics

Basic
Market capitalization
$4.1b
Enterprise Value
$2.2b
Net debt
positive
Cash
$1.9b
Shares outstanding
86.4m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
108.85 | 84.39
EV/Sales
59.61 | 46.22
EV/FCF
negative
P/B
2.24
Financial Health
Equity Ratio
86.18%
Return on Equity
-18.96%
ROCE
-23.18%
ROIC
-163.32%
Debt/Equity
0.00
Financials (TTM | estimate)
Revenue
$37.7m | $48.6m
EBITDA
$-455.2m | $-507.8m
EBIT
$-474.4m
Net Income
$-385.7m | $-476.9m
Free Cash Flow
$-307.9m
Growth (TTM | estimate)
Revenue
-86.13% | 30.26%
EBITDA
-63.15% | -13.51%
EBIT
-58.87%
Net Income
-77.61% | -30.22%
Free Cash Flow
-82.15%
Margin (TTM | estimate)
Gross
-
EBITDA
-1,208.33% | -1,044.78%
EBIT
-1,259.20%
Net
-1,023.64% | -981.32%
Free Cash Flow
-817.14%
More
EPS
$-4.48
FCF per Share
$-3.56
Short interest
28.19%
Employees
393.00
Rev per Employee
$90.00k
Show more

Is CRISPR Therapeutics AG a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,948 stocks worldwide.

CRISPR Therapeutics AG Stock Analysis

Unlock Scores for Free

Analyst Opinions

34 Analysts have issued a CRISPR Therapeutics AG forecast:

21x Buy
62%
12x Hold
35%
1x Sell
3%

Analyst Opinions

34 Analysts have issued a CRISPR Therapeutics AG forecast:

Buy
62%
Hold
35%
Sell
3%

Financial data from CRISPR Therapeutics AG

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
38 38
86% 86%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 195 195
6% 6%
518%
- Research and Development Expense 317 317
13% 13%
841%
-455 -455
63% 63%
-1,208%
- Depreciation and Amortization 19 19
2% 2%
51%
EBIT (Operating Income) EBIT -474 -474
59% 59%
-1,259%
Net Profit -386 -386
78% 78%
-1,024%

In millions USD.

Don't miss a Thing! We will send you all news about CRISPR Therapeutics AG directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

CRISPR Therapeutics AG Stock News

Neutral
GlobeNewsWire
5 days ago
-New Phase 1 clinical data for CTX310™ continues to demonstrate dose-dependent reductions in triglycerides (TG) and low-density lipoprotein (LDL), with peak reduction of up to 82% in TG and up to 86% in LDL, with a well-tolerated safety profile-
Positive
The Motley Fool
7 days ago
Is it time to reload your portfolio with some new picks? That's easier said than done right now.
Positive
The Motley Fool
9 days ago
If you're looking to add growth to your portfolio, biotech stocks can be a great choice. Exciting research is happening in these companies' labs, and in some cases, game-changing treatment candidates are approaching important milestones or even going over the finish line.
More CRISPR Therapeutics AG News

Company Profile

CRISPR Therapeutics AG engages in the development and commercialization of therapies derived from genome-editing technology. Its proprietary platform CRISPR/Cas9-based therapeutics allows for precise and directed changes to genomic DNA. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan and Craig Mellow in 2014 and is headquartered in Zug, Switzerland.

Head office Switzerland
CEO Samarth Kulkarni
Employees 393
Founded 2013
Website crisprtx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today